Do you need an antibody that isn’t commercially available to characterize a new target, or are you dissatisfied with the one you’re currently using? With ProteoGenix’s custom monoclonal antibody service, you can obtain a tailor-made antibody fully validated in the application of your choice.
Rest assured you’ll receive an antibody optimized for your specific application (ELISA, sandwich ELISA, IF, IP, IHC, FC, WB…)
Our services meet demands at every scale, from laboratory applications to industrial use.
Receive your monoclonal antibody in as little as 4 weeks!
Phage display, hybridoma, and single B cell screening—a complete set of technologies to solve all your challenges.
Your project strategy and management are led by a PhD-level expert.
With our antibody libraries, generate monoclonal antibodies without using animals!
Our custom monoclonal antibody development service includes antigen design and production from the sequence provided, antibody generation using one of our three proprietary platforms, as well as antibody production and purification.
This service can also be supplemented with optional steps such as conjugation to peroxidase or fluorochromes, or conversion for recombinant production (transient or stable production).
As experts in peptide and protein production, ProteoGenix can utilize a wide range of macromolecules as antigens, including:
Antibodies can be generated using one of our three monoclonal antibody generation platforms (hybridoma, phage display, or single B cell). The generation timeline depends mainly on the chosen method, ranging from 4 to 15 weeks.
| Method | Turnaround Time (may vary depending on the project) |
|---|---|
| Phage Display – Naïve Library | From 4 weeks |
| Phage Display – Immune Library | From 10 weeks |
| Single B cell screening | From 7 weeks |
| Hybridoma generation | From 9 weeks |
The generated antibodies can be produced using various methods to meet your specific needs, from small-scale to large-scale production.
| Method | Application |
|---|---|
| Hybridoma cell culture | Small-scale production |
| Mouse ascites production | Small-scale production |
| High-throughput antibody production | Parallel testing of dozens or hundreds of sequences |
| Transient antibody production | Small-scale production |
| Stable cell line generation | Large-scale and long-term production (manufacturing) |
If needed, our teams can conjugate the produced antibodies with various peroxidases or fluorochromes to suit your application, whether for flow cytometry, detection assays, or other uses.
Interested in learning more? Feel free to contact our experts by clicking here.
In this video, discover how ProteoGenix supported every step—from stabilizing a challenging GPCR to engineering the final CAR construct. Watch how expert guidance and advanced tech turned an ambitious idea into a successful program.
ProteoGenix offers three custom monoclonal antibody development platforms. Why three? To ensure we can provide a solution no matter the antigen you need to target, even if it’s non-immunogenic, toxic, or a novel target with limited information.
We work for your success. Your satisfaction with the antibodies we produce is our top priority. For this reason, we offer “application guaranteed” packages for research and diagnostic applications, ensuring optimal performance in your specific application.
Here’s how it works:
We guarantee performance in the following applications:
This is the best way we have found to ensure you receive an antibody that perfectly meets your needs.
Our diverse antibody development platforms allow us to deliver custom monoclonal antibodies with guaranteed performance in your chosen application. To illustrate our process, here are two case studies where you’ll find:
Please note, our guarantees consider both results obtained by ProteoGenix and successful outcomes of supplied antibodies in your own lab setting.
“We are thrilled with the success we’ve achieved through our collaboration with ProteoGenix in developing monoclonal antibodies targeting our protein. The antibodies they produced were not only highly selective but also demonstrated exceptional affinity for our target, significantly advancing our research. ProteoGenix impressed us with their efficiency and speed throughout the process. Their commitment to providing excellent customer service made our experience even better, as they were always available to address our questions and concerns. We highly recommend ProteoGenix to anyone in need of high-quality antibody development.”
Verónica Alcolea, Product Development Manager, Telum Therapeutics, Spain
JP Barnier et al., The minor pilin PilV provides a conserved adhesion site throughout the antigenically variable meningococcal type IV pilus. PNAS 118, (45) e2109364118 (2021).
https://doi.org/10.1073/pnas.2109364118
H Cerutti et al., Large scale production and characterization of SARS-CoV-2 whole antigen for serological test development. J Clin Lab Anal 35, (4) 23735 (2021).
https://doi.org/10.1002/jcla.23735
N Yacov et al., MOSPD2 is a therapeutic target for the treatment of CNS inflammation. Clin Exp Imm 201, (2) 105-20 (2020).
https://doi.org/10.1111/cei.13448
PC Maity et al., IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. PNAS 117, (8) 4320-27 (2020).
https://doi.org/10.1073/pnas.1913810117
M Fresquet et al., Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain. J Autoimm 106, 102308 (2020).
https://doi.org/10.1016/j.jaut.2019.102308
P Cunha et al., Expansion, isolation and first characterization of bovine Th17 lymphocytes. Nature Sci Rep 9, 16115 (2019).
https://doi.org/10.1038/s41598-019-52562-2
M Krifa et al., Limoniastrum guyonianum aqueous gall extract induces apoptosis in human cervical cancer cells involving p16INK4A re-expression related to UHRF1 and DNMT1 down-regulation. J Exp Clin Canc Res 32, (30) (2013).
https://doi.org/10.1186/1756-9966-32-30
E Faure et al., Probable presence of an ubiquitous cryptic mitochondrial gene on the antisense strand of the cytochrome oxidase I gene. Biol Direct 6, (56) (2011).
https://doi.org/10.1186/1745-6150-6-56
Essentials insights into antibody generation methods, applications, challenges and future trends
